How shall we treat locally advanced triple negative breast cancer?
Paulo LuzDavid DiasAna FortunaLuis BretesBeatriz GosalbezPublished in: F1000Research (2019)
Triple negative breast cancer (TNBC) has been shown to respond to neoadjuvant chemotherapy (NACT). It has been established that achieving pathological complete response (pCR) for certain aggressive subtypes of breast cancer, including HER-2 (over-expressed) and TNBC, provides an important surrogate marker for predicting long-term clinical response and survival outcomes. How to increase the number of patients that achieve pCR remains challenging. Platinum-based NACT seems to be part of the solution and capecitabine, an active drug in metastatic breast cancer, but not a standard one in earlier stages may have found its place in the adjuvant setting.
Keyphrases
- locally advanced
- neoadjuvant chemotherapy
- metastatic breast cancer
- rectal cancer
- squamous cell carcinoma
- end stage renal disease
- phase ii study
- radiation therapy
- lymph node
- sentinel lymph node
- chronic kidney disease
- ejection fraction
- newly diagnosed
- early stage
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- adverse drug